AN ORAL MICROEMULSION-BASED FORMULATION FOR THE DELIVERY OF CABAZITAXEL AND PIPERINE AND USES THEREOF

Cabazitaxel is the newest version of taxanes and is regarded as a promising drug for the 5 management of various cancers. Like other taxanes, this drug also poses a challenge of solubility and permeability, resulting in a poor oral bioavailability. The present study explores a scalable and economic...

Full description

Saved in:
Bibliographic Details
Main Authors JITENDRA SINGH RAJAWAT, KAMBLE RAVINDRA KESHAVRAO, RAJENDRA PAL SINGH RATHORE, REHAN UDDIN
Format Patent
LanguageEnglish
Published 31.01.2024
Online AccessGet full text

Cover

More Information
Summary:Cabazitaxel is the newest version of taxanes and is regarded as a promising drug for the 5 management of various cancers. Like other taxanes, this drug also poses a challenge of solubility and permeability, resulting in a poor oral bioavailability. The present study explores a scalable and economic nanoformulation in the microemulsion form for the oral delivery of cabazitaxel. The developed system substantially improved the anticancer activity of the drug on the breast cancer cell lines and in vivo cancer models. Piperine was also loaded in the 10 microemulsion and it was observed that the incorporation of piperine resulted in an oral formulation with substantially higher oral bioavailability of CBZ vis-à-vis plain drug as well as the microemulsion. The findings provide an inference that biocompatible microemulsions can enhance the oral bioavailability and anticancer activity of CBZ, which was further improved after incorporation of piperine.
Bibliography:Application Number: ZA20230005238